Krynica Vitamin SA (KVT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Krynica Vitamin SA stock PLN 20.49, price PLN 12.85, upside +59.5%, quality 67 out of 100. Rating: strongly undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 7.44 PLN – 21.26 PLN · fair‑value band 15.36 PLN – 25.61 PLN · the 12.85 PLN price screens below the 20.49 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Krynica Vitamin in your weekly email
Every Wednesday you see whether Krynica Vitamin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Krynica Vitamin S.A. produces and sells non-alcoholic and low-alcoholic beverages in Poland, Germany, the United Kingdom, the Czech Republic, Slovakia, and internationally.
Show moreShow less
It offers energy drink; functional drinks, such as vitamin cocktails, and diet supplements; carbonated soft drink includes cola type, orange type, and lemon type beverages; alcopops; coffee; and dairy drinks.
In addition, the company packages and markets its products in the form of aluminum cans, PET bottles, and glass bottles, as well as provides contract manufacturing services for other brands. Krynica Vitamin S.A. was incorporated in 2011 and is headquartered in Warsaw, Poland.
Krynica Vitamin S.A. operates as a subsidiary of Zinat Sp. Z O.O.
Stock analysis
Krynica Vitamin SA (KVT) currently trades at 12.85 PLN, while our model-based Fair Value estimate is 20.49 PLN, implying the stock looks roughly 37% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 26.37 PLN per share, and 20 of the 25 models we run sit above the 12.85 PLN price.
Bear case: the Dividend Discount group reads lowest at 3.82 PLN, and 5 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 15.36 PLN (bear) to 25.61 PLN (bull), the price of 12.85 PLN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Krynica Vitamin SA reported revenue of 356M PLN in FY2025 versus 395M PLN in FY2021, a compound −2.6%/yr. Reported net income was 12.0M PLN in FY2025, compounding −6.4%/yr from FY2021.
Key figures
Market cap 157M PLN (≈ $39.8M) Micro · P/E ratio 18.9 · P/S ratio 0.42 · EPS (TTM) 0.6800 PLN · Net margin 2.8% · Return on equity 10.5% · Return on assets (EBIT) 6.7% (5-year average) · Operating margin 6.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 36% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −23% fair-value upside, at 59%, KVT screens cheaper than that median.
Fair Value models
Bear15.36 PLNFair Value 20.49 PLNBull25.61 PLN
Price 12.85 PLN · Upside +59.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5813 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
Start year 2020 (pandemic). Over 10 years: +8.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.2% vs 16.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about −10.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Beverages - Non-Alcoholic · 80 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Above median
Fair Value upside+59.5% · Top 25%
Profitability
Return on equity (12 months)10.5% · Below median
Return on assets6.4% · Below median
Net margin (12 months)2.8% · Bottom 25%
Operating margin (12 months)6.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.8% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Beverages - Non-Alcoholic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Krynica Vitamin SA Fair Value". https://www.fairvalue-calculator.com/stock/KVT
Frequently asked questions
Is Krynica Vitamin SA (KVT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 20.49 PLN versus a price of 12.85 PLN, about +59% upside (undervalued).
What is the fair value of KVT?
Our model-based fair value for Krynica Vitamin SA is 20.49 PLN (as of Nov 7, 2026), built from audited fundamentals. The current price: 12.85 PLN.
What is the quality score of KVT?
Krynica Vitamin SA has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Krynica Vitamin SA (KVT)?
Our model-based price target is the fair value of 20.49 PLN (as of Nov 7, 2026) from 25 valuation models. Cautious scenario 15.36 PLN, optimistic scenario 25.61 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Krynica Vitamin SA stock forecast for 2026?
Our models put fair value at 20.49 PLN, about +59% upside versus a price of 12.85 PLN (undervalued). Cautious scenario 15.36 PLN, optimistic scenario 25.61 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Krynica Vitamin SA (KVT)?
Krynica Vitamin SA reported trailing-twelve-month revenue of about 374M PLN (latest available figure, as of Nov 7, 2026).
What growth is priced into Krynica Vitamin SA (KVT)?
For today's price to be fair in a discounted-cash-flow model, Krynica Vitamin SA would have to grow free cash flow by -8.1 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of KVT use?
Our models discount Krynica Vitamin SA at 9.3 %: a base by market capitalisation (nano), damped by beta 0.07, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Krynica Vitamin SA that is -8.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Krynica Vitamin SA (KVT) delivered so far?
Over the past 5 years revenue at Krynica Vitamin SA grew -4.4 % a year. The price currently implies free-cash-flow growth of -8.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Krynica Vitamin SA (KVT) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Krynica Vitamin SA (-8.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Krynica Vitamin SA (KVT)?
The free-cash-flow yield on the price is 14.41 %: that much free cash flow Krynica Vitamin SA produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Krynica Vitamin SA (KVT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Krynica Vitamin SA it is 20.49 PLN per share (as of Nov 7, 2026), against a price of 12.85 PLN. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Krynica Vitamin SA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, KVT trades below its calculated fair value: price 12.85 PLN, fair value 20.49 PLN, a gap of about +59% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KVT?
No. The price is what the market pays today (12.85 PLN); the fair value is what the company's own numbers justify (20.49 PLN). For Krynica Vitamin SA the two are 7.64 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Krynica Vitamin SA worth?
The market values Krynica Vitamin SA at about 157M PLN (market capitalisation, as of Nov 7, 2026). Per share that is 12.85 PLN; our models calculate a fair value of 20.49 PLN per share.
What do the bullish and bearish scenarios say about KVT?
Our models span a range for Krynica Vitamin SA: cautious scenario 15.36 PLN, base 20.49 PLN, optimistic 25.61 PLN per share (as of Nov 7, 2026, price 12.85 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KVT?
Krynica Vitamin SA trades at a price-to-earnings ratio of 18.9 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 20.49 PLN is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 10.8. Other multiples: P/B 1.5, P/S 0.4, EV/EBITDA 4.8.
How solid is the balance sheet of Krynica Vitamin SA (KVT)?
Balance-sheet figures for Krynica Vitamin SA (as of Nov 7, 2026): return on equity 10.5%, debt of 0.10 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is KVT from its 52-week high?
Krynica Vitamin SA trades at 12.85 PLN, about 4% below its 52-week high of 13.40 PLN and 36% above the low of 9.45 PLN (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 20.49 PLN is for.
Which stocks are comparable to Krynica Vitamin SA?
From the same area (Consumer Defensive) we also value The Coca-Cola Company, PepsiCo, Inc, Monster Beverage Corporation, Nongfu Spring Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Krynica Vitamin SA stock attractive at the current price?
The data as of Nov 7, 2026: price 12.85 PLN, calculated fair value 20.49 PLN (+59%), Quality Score 67/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KVT calculated?
We run Krynica Vitamin SA through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 20.49 PLN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Krynica Vitamin SA currently trades 37% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Krynica Vitamin SA (KVT)?
The closing price on Nov 6, 2026 was 12.85 PLN. Our model-based fair value is 20.49 PLN, about +59% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Krynica Vitamin SA right now?
The price is below even our cautious bear case (15.36 PLN). The market is more pessimistic than our downside scenario. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Krynica Vitamin SA (KVT) come from?
Earnings per share at Krynica Vitamin SA grew +22.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +29.7 %, EBIT margin −4.5 %, tax rate +0.7 %, residual (interest, one-offs) −1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Krynica Vitamin SA
How large is the market capitalisation of Krynica Vitamin SA (KVT)?
The market capitalisation of Krynica Vitamin SA is 157M PLN (≈ $39.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Krynica Vitamin SA (KVT)?
The price-to-sales ratio of Krynica Vitamin SA is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Krynica Vitamin SA (KVT)?
Earnings per share at Krynica Vitamin SA are 0.6800 PLN (price ÷ EPS = P/E 18.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Krynica Vitamin SA (KVT)?
The net margin of Krynica Vitamin SA is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Krynica Vitamin SA (KVT)?
The return on equity (ROE) of Krynica Vitamin SA is 10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Krynica Vitamin SA (KVT)?
On an EBIT basis the return on assets of Krynica Vitamin SA is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Krynica Vitamin SA (KVT)?
The operating margin of Krynica Vitamin SA is 6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Krynica Vitamin SA (KVT)?
Revenue at Krynica Vitamin SA is growing +10.8% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Krynica Vitamin SA (KVT)?
Earnings per share at Krynica Vitamin SA are growing −22.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Krynica Vitamin SA (KVT) carry?
The net debt of Krynica Vitamin SA is 22.6M PLN (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Krynica Vitamin SA in the live analysis
One click puts Krynica Vitamin SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026